A 2024 study published in The Journal of the American Medical Association and CDC surveillance data indicate that RSV vaccine effectiveness decreases in older adults over time, prompting questions about long-term protection strategies.
Story Snapshot
- RSV vaccines show strong initial protection of 77-89% effectiveness in older adults during first months
- Real-world data confirms vaccines prevent severe hospitalizations and emergency department visits
- Questions emerge about duration of protection and need for ongoing surveillance
- Three FDA-approved vaccines now available: Pfizer’s Abrysvo, GSK’s Arexvy, and Moderna’s mResvia
Initial Vaccine Performance Exceeds Expectations
RSV vaccines for older adults demonstrated remarkable initial effectiveness during the 2023-2024 season, with protection rates reaching 77-89% against severe respiratory outcomes. The three FDA-approved vaccines, Pfizer’s Abrysvo, GSK’s Arexvy, and Moderna’s mResvia, proved particularly effective at preventing hospitalizations and emergency department visits among adults aged 60 and older. This success marked a significant breakthrough after decades of failed vaccine attempts dating back to the 1960s.
NEJM researchers reported the vaccines were effective across subgroups, including immunocompromised individuals. CDC surveillance data confirmed no significant waning of protection during the first RSV season following vaccination. Healthcare systems reported notable reductions in RSV-related admissions, demonstrating the vaccines’ real-world impact on reducing disease burden among America’s senior citizens.
Historical Context Reveals Decades of Challenges
RSV vaccine development faced catastrophic setbacks in the 1960s when the first formalin-inactivated vaccine caused enhanced respiratory disease in children, effectively halting progress for decades. This tragic outcome forced researchers to rely on costly monoclonal antibody treatments like palivizumab for high-risk infants throughout the 1990s. The breakthrough came through advances in understanding RSV immunology, particularly the critical role of the pre-fusion F protein in vaccine design.
The pharmaceutical industry’s persistence finally paid off in 2023 with FDA approval of three distinct RSV vaccines for older adults. This achievement represented not just scientific progress but also a vindication of American innovation in vaccine technology. For families who have watched elderly relatives suffer from severe RSV complications, these vaccines offered hope for protecting loved ones during their most vulnerable years.
Effectiveness Questions Demand Ongoing Vigilance
While initial effectiveness data provides encouraging news, experts emphasize the critical need for continued surveillance to assess long-term vaccine durability. The CDC maintains its recommendation for adults 60 and older based on shared clinical decision-making with healthcare providers. However, uncertainty remains about whether protection will sustain through subsequent RSV seasons, requiring ongoing monitoring and potential adjustments to vaccination strategies.
https://t.co/z1Tu03rDj4 virus always mutates imho
— Just MAGAlous dahling! (@LarrysNana) August 28, 2025
Researchers stress that increased vaccine uptake among eligible populations remains essential for maximizing public health benefits. The success of these vaccines demonstrates that American medical innovation can overcome seemingly insurmountable challenges when guided by sound science and persistent effort. For conservative Americans who value individual responsibility and medical freedom, these vaccines represent a voluntary tool for protecting personal health while reducing strain on healthcare systems.
Sources:
Real-world effectiveness of respiratory syncytial virus vaccines in older adults
RSV Vaccine Clinical Guidance for Adults
RSV vaccines effective but more people need to get them
Historical perspectives on RSV vaccine development
